Lowdon Douglas W, Quinn Catherine, Mole Pat, Leese Graham P
Section of Ageing and Health, Department of Medicine, Ninewells Hospital, Dundee DD1 9SY.
Scott Med J. 2006 May;51(2):32-5. doi: 10.1258/RSMSMJ.51.2.32.
Currently fracture sufferers are not being assessed or treated for osteoporosis. Osteoporosis guidelines differ in their secondary prevention recommendations, with the Scottish Intercollegiate Guideline Network (SIGN) advocating bone densitometry in all fracture patients and anti-resorptive treatment only if evidence-based criteria are confirmed, but the National Institute of Clinical Excellence (NICE) technology appraisal recommends treatment for all older females without this bone densitometry confirmation. We aimed to determine the rate of referral for bone densitometry, the numbers achieving SIGN criteria for anti-resorptive therapy, and the rate of osteoporosis treatment in patients with hip fracture
A retrospective review of all patients older than 65 years who had sustained a hip fracture in Tayside between April 2003 and July 2005 was performed
Only 8.6% of hip fracture patients underwent bone densitometry, of which 90.6% of females older than 75 years met SIGN criteria for anti-resorptive treatment. 74.3% of all patients referred for bone densitometry were treated with an anti-resorptive agent, compared to only to 12.7% of the large majority group who were not assessed for osteoporosis
Osteoporosis investigation and therefore treatment remains sub-optimal in hip fracture patients. Almost all females, older than 75 years, with a hip fracture met evidence-based criteria for anti-resorptive treatment. NICE guidance, recommending anti-resorptive treatment without bone densitometry confirmation of reduced bone mineral density, should maybe be implemented for this specific group of patients in an attempt to increase osteoporosis treatment rates.
目前骨折患者未接受骨质疏松症评估或治疗。骨质疏松症指南在二级预防建议方面存在差异,苏格兰校际指南网络(SIGN)主张对所有骨折患者进行骨密度测定,只有在循证标准得到确认时才进行抗吸收治疗,但英国国家临床优化研究所(NICE)技术评估建议对所有老年女性进行治疗,无需进行这种骨密度测定确认。我们旨在确定骨密度测定的转诊率、达到抗吸收治疗SIGN标准的人数以及髋部骨折患者的骨质疏松症治疗率。
对2003年4月至2005年7月在泰赛德发生髋部骨折的所有65岁以上患者进行回顾性研究。
仅8.6%的髋部骨折患者接受了骨密度测定,其中75岁以上女性中有90.6%符合抗吸收治疗的SIGN标准。所有接受骨密度测定转诊的患者中有74.3%接受了抗吸收药物治疗,相比之下,未接受骨质疏松症评估的大多数患者中只有12.7%接受了治疗。
髋部骨折患者的骨质疏松症调查及因此的治疗仍未达到最佳状态。几乎所有75岁以上髋部骨折的女性都符合抗吸收治疗的循证标准。对于这一特定患者群体,或许应实施NICE指南,即在未通过骨密度测定确认骨矿物质密度降低的情况下推荐抗吸收治疗,以提高骨质疏松症治疗率。